GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CYRX
Cryoport provides logistics solutions for the transportation of biomaterials at ultra-low temperatures. Its stock price reflects the growth of the cell and gene therapy industry, which critically depends on a reliable cold chain.
Share prices of companies in the market segment - Logist it
Cryoport provides critical temperature-controlled logistics solutions for the biopharmaceutical industry, ensuring the safety of cell therapies and vaccines. We classify this as "IT logistics." The chart below illustrates the overall dynamics of this unique and growing sector.
Broad Market Index - GURU.Markets
Cryoport is a leader in temperature-controlled logistics for the life sciences industry, facilitating the transportation of cell and gene therapies. As a critical component, the company is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Cryoport's performance.
Change in the price of a company, segment, and market as a whole per day
CYRX - Daily change in the company's share price CYRX
The daily price change of Cryoport, a leader in cell therapy logistics, reflects the state of the biotech sector. Change_co shows sensitivity to the increase in the number of clinical trials. This metric is key to analyzing the biomanufacturing and logistics sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Logist it
Cryoport, Inc. is a leader in cell and gene therapy logistics. This chart highlights the sector's high volatility. Comparing it to CYRX, a key player in biotech, helps position it as a bet on the industry's growth.
Daily change in the price of a broad market stock, index - GURU.Markets
Cryoport is a leader in cold chain logistics for the life sciences industry. Its services are critical for the transport of cell and gene therapies. Cryoport's business serves as a barometer for the health of the entire biotech industry. The chart below shows overall market volatility, which can be used to assess the performance of this niche leader.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CYRX
For Cryoport, Inc., year-over-year growth is a sign of the growth of the cell and gene therapy industry. This logistics company's 12-month market capitalization growth is directly related to the growing number of clinical trials and commercial drugs requiring the transportation of biomaterials at ultra-low temperatures, a core competency of the company.
Annual dynamics of market capitalization of the market segment - Logist it
Cryoport, Inc. is a leader in temperature-controlled logistics for the life sciences industry. Its services are critical to the transport of cell and gene therapies. This chart illustrates how its indispensable role in this rapidly growing ecosystem enables its accelerated growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cryoport, providing logistics for cell and gene therapy, is a gold mine for biotech. Demand for its services is growing alongside the development of this cutting-edge field of medicine. The company's stock price reflects this long-term trend, making it an infrastructure bet on the future of healthcare.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CYRX
The dynamics of Cryoport, a logistics company, depend on the cell and gene therapy sector. The monthly fluctuations on the chart reflect demand for its cryogenic transportation services, which is directly linked to the number of clinical trials and commercial launches of new cell therapy products.
Monthly dynamics of market capitalization of the market segment - Logist it
Cryoport is a leader in cell and gene therapy logistics. The company ensures the transportation of critical biomaterials at cryogenic temperatures, which is essential for the success of treatments. The graph below shows the dynamics of the specialized logistics sector, which is growing alongside the biopharmaceutical industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cryoport provides logistics solutions for cell and gene therapy requiring ultra-low temperatures. The company is a key player in innovative medicine, and demand for its services is growing alongside the sector. Its shares can outperform the market, driven by breakthroughs in biotech rather than the overall economic situation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CYRX
Cryoport provides logistics solutions for cell and gene therapy at ultra-low temperatures. Its weekly stock price reflects the growth of this innovative medical sector. As more therapies are approved and used, demand for its unique services increases.
Weekly dynamics of market capitalization of the market segment - Logist it
Cryoport, like other companies serving the cell and gene therapy sector, depends on the overall growth of this innovative industry. Weekly stock price movements in this segment reflect the overall pace of development in advanced medicine. The chart shows how the company is tracking this overall trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cryoport provides logistics solutions for cell and gene therapy, a critical niche in a rapidly growing sector. The chart shows how the company's stock correlates with a biotech index, rather than the broader market, serving as a barometer for the health of the entire regenerative medicine industry.
Market capitalization of the company, segment and market as a whole
CYRX - Market capitalization of the company CYRX
Cryoport, Inc.'s stock chart is a story about cell and gene therapy logistics. Its market cap reflects the growing need to transport biological materials at ultra-low temperatures. This is a bet on the company becoming a key infrastructure link in the medicine of the future.
CYRX - Share of the company's market capitalization CYRX within the market segment - Logist it
Cryoport, Inc. is a market leader in cell and gene therapy logistics, holding a dominant share in cryogenically-temperature biomaterial shipments. Its market capitalization reflects its critical role in the supply chain for this rapidly growing sector.
Market capitalization of the market segment - Logist it
Cryoport provides ultra-cold logistics for cell and gene therapy. How big is this revolutionary industry? The graph below shows the overall market capitalization of IT logistics. Its growth reflects the importance of a flawless cold chain for the future of personalized medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Cryoport graph is a visualization of the cost of cold chain logistics for life sciences. The company, a leader in ultra-low-temperature cell and gene therapy logistics, is growing in value alongside the development of this medical sector. This diagram illustrates how critical infrastructure is becoming indispensable.
Book value capitalization of the company, segment and market as a whole
CYRX - Book value capitalization of the company CYRX
Cryoport's core assets include its global network of logistics centers equipped with cryogenic equipment and specialized containers for transporting biomaterials at ultra-low temperatures. Its book value reflects the value of this unique infrastructure. The chart below shows how it has expanded.
CYRX - Share of the company's book capitalization CYRX within the market segment - Logist it
Cryoport is a logistics operator for cell and gene therapy, and its assets include a network of global distribution centers with cryogenic storage facilities. These physical facilities are a critical link in the future of medicine. The graph shows the share of this unique "cold chain" supply chain the company controls.
Market segment balance sheet capitalization - Logist it
Cryoport provides logistics services for cell and gene therapy. Its model is unique in a capital-intensive industry. The industry's asset chart reflects the value of laboratories. Cryoport, on the other hand, is investing in a fleet of specialized cryogenic containers.
Book value of all companies included in the broad market index - GURU.Markets
Cryoport's assets include a global network of specialized logistics centers and unique containers for transporting biomaterials at ultra-low temperatures. The graph below shows the growth of this critical infrastructure for cell and gene therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CYRX
Cryoport's assets are unique containers and logistics centers. The market pays a significant premium for their critical role in the cell and gene therapy supply chain. The chart shows how this premium has changed for their unique niche.
Market to book capitalization ratio in a market segment - Logist it
Cryoport provides logistics solutions for cell and gene therapy requiring ultra-low temperatures. Its value lies in its unique infrastructure and expertise. The chart shows the market premium it commands for its critical role in modern medicine.
Market to book capitalization ratio for the market as a whole
Cryoport provides logistics solutions for cell and gene therapy requiring ultra-low temperatures. Its value lies in creating an essential infrastructure for the future of medicine. Given the average valuation on this chart, the market values it as a critical partner for hundreds of biotech companies, not just a logistics provider, creating a significant premium to its balance sheet.
Debts of the company, segment and market as a whole
CYRX - Company debts CYRX
Cryoport provides logistics solutions for cell and gene therapy requiring ultra-low temperatures. This chart shows how the company is investing in expanding its unique infrastructure. Debt financing is being used to acquire specialized containers and build a global network to support vital supplies.
Market segment debts - Logist it
Cryoport provides critical logistics solutions for the biopharmaceutical industry, transporting cell and gene therapies at ultra-low temperatures. This rapidly growing market requires investment in specialized equipment and a global network. This chart shows how the company's debt policy reflects its strategy to build the infrastructure for the medicine of the future.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CYRX
Cryoport provides logistics solutions for cell and gene therapy, requiring specialized equipment. This chart shows how the company uses debt to invest in its unique cold chain infrastructure. It helps assess the financial sustainability of its strategy as demand for biomaterial transportation grows.
Market segment debt to market segment book capitalization - Logist it
Cryoport provides logistics solutions for cell and gene therapy requiring ultra-low temperatures. This chart shows the debt burden in the specialized logistics sector, helping to understand how companies in this critical niche are funding the creation of their unique infrastructure and global expansion.
Debt to book value of all companies in the market
Cryoport provides logistics solutions for cell and gene therapy, which requires investment in specialized equipment. This chart, showing the overall market debt burden, allows us to assess how the company finances its unique infrastructure. Does it leverage debt, following general trends, or rely on equity?
P/E of the company, segment and market as a whole
P/E - CYRX
Cryoport provides critical logistics solutions for cell and gene therapy, transporting biomaterials at cryogenic temperatures. This chart shows how much investors value the "picks and shovels" of the biotech revolution. The trend reflects the growing number of clinical trials and commercial launches of cell therapies.
P/E of the market segment - Logist it
Cryoport provides critical logistics solutions for the life sciences industry. The company transports temperature-sensitive materials, such as gene therapy cells, at cryogenic temperatures. This chart shows the average rating for the IT logistics sector, reflecting how the market values the infrastructure supporting the biopharma revolution.
P/E of the market as a whole
Cryoport provides logistics solutions for the transport of critical biomaterials at cryogenic temperatures (for example, for cell therapy). Demand for its services is fueled by growth in the regenerative medicine sector. This long-term trend makes its business less dependent on short-term economic cycles, as reflected in this chart.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CYRX
Cryoport, Inc. provides temperature-controlled logistics solutions critical for the transportation of cell and gene therapy materials. This graph reflects the expected growth of the entire biopharmaceutical industry. The company's valuation is driven by the number of clinical trials and commercial drugs requiring its unique logistics services.
%20P%2FE%20CYRX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CYRX&v=1772561569771 "Chart of the company's future (projected) P/E CYRX")
Future (projected) P/E of the market segment - Logist it
Cryoport provides logistics solutions for the biopharmaceutical industry, transporting critical materials such as cells and tissue at ultra-low temperatures. This chart reflects the expected growth of cell and gene therapy. Comparing its revenue projections with the sector reveals the value of its unique services.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Logist%20it&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Logist-it&v=1772561569851 "Future (projected) P/E graph of the market segment - Logist it")
Future (projected) P/E of the market as a whole
Cryoport provides logistics solutions for the biopharmaceutical industry, transporting cell and gene therapies at ultra-low temperatures. The company's growth is driven by advances in regenerative medicine. This general sentiment trend is less important than the pace of development and commercialization of cell therapies, which are the primary drivers of demand.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772561569888 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CYRX
Cryoport, Inc. provides temperature-controlled logistics solutions for cell and gene therapy. The company's revenue depends on the growth of clinical trials and commercialization of drugs in this innovative field of medicine. This chart illustrates how Cryoport is becoming an integral part of the biopharmaceutical industry's infrastructure.
Profit of companies in the market segment - Logist it
Cryoport provides logistics solutions for the biopharmaceutical industry, specializing in the transportation of critical biomaterials at cryogenic temperatures. The company's growth is directly linked to the development of cell and gene therapy. This chart shows the overall dynamics of the IT logistics sector, reflecting how investments in advanced medicine are driving demand for sophisticated logistics services.
Overall market profit
Cryoport provides logistics solutions for the biopharmaceutical industry, transporting critical biological materials at ultra-low temperatures. The company's growth is directly linked to the development of cell and gene therapy. Cryoport is a vital part of the infrastructure for the medicine of the future, and its success reflects the progress in this cutting-edge sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CYRX
Cryoport provides logistics solutions for cell and gene therapies requiring ultra-low temperatures. This graph reflects the expected growth of the entire biopharmaceutical industry. As more new therapies enter the market, demand for Cryoport's unique services increases, which determines its future profitability.
%20profit%20of%20the%20company%20CYRX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CYRX&v=1772561570205 "Graph of future (projected) profit of the company CYRX")
Future (predicted) profit of companies in the market segment - Logist it
Cryoport, Inc. provides temperature-controlled logistics solutions for cell and gene therapy. This chart illustrates profitability forecasts for the life sciences sector. It helps understand how the growth of innovative biopharmaceuticals, which require complex cold chain management, directly impacts Cryoport's prospects.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Logist%20it&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Logist-it&v=1772561570239 "Graph of future (predicted) profits of companies in a market segment - Logist it")
Future (predicted) profit of the market as a whole
The dynamics in this chart reflect expectations for a company providing logistics services to the biopharmaceutical industry. Cryoport's profit forecast hinges on the growth of clinical trials and the commercialization of cell and gene therapies, which require transportation at ultra-low temperatures. This is a bet on the infrastructure of advanced medicine.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772561570300 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CYRX
Cryoport provides critical logistics solutions for cell and gene therapy. This chart demonstrates how highly the market values its unique niche. The multiple reflects the growing demand for its services as more biotech drugs are approved and enter the market.
P/S market segment - Logist it
Cryoport provides temperature-controlled logistics solutions for cell and gene therapy. The company's revenue is growing alongside the development of this cutting-edge medical sector. This chart shows the average valuation in the specialized logistics sector, helping to understand the premium the market is willing to pay for Cryoport's revenue, which serves a critical industry.
P/S of the market as a whole
Cryoport provides logistics solutions for the biopharmaceutical industry, specializing in the transportation of critical materials at ultra-low temperatures. Its revenue is growing with the development of cell and gene therapy. This graph, which displays average revenue estimates for Cryoport, helps us understand the market premium placed on its unique infrastructure role in the medicine of the future.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CYRX
Cryoport provides logistics solutions for the biopharmaceutical industry, transporting critical materials (cells and tissues) at ultra-low temperatures. This chart shows how investors estimate future revenues, which are directly linked to the growth of the cell and gene therapy markets, which require complex cold chain supply chains.
%20P%2FS%20CYRX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CYRX&v=1772561570560 "The graph of the company's future (projected) P/S CYRX")
Future (projected) P/S of the market segment - Logist it
Cryoport provides temperature-controlled logistics solutions for the life sciences industry, which is critical for cell and gene therapy. This chart compares the company's estimated future sales with other IT logistics firms. It reflects investor expectations for the growth of the regenerative medicine sector, which directly drives demand for Cryoport's services.
%20P%2FS%20market%20segment%20graph%20-%20Logist%20it&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Logist-it&v=1772561570616 "Future (projected) P/S market segment graph - Logist it")
Future (projected) P/S of the market as a whole
Cryoport provides logistics solutions for cell and gene therapies requiring ultra-low temperatures. Demand for its services is growing alongside the development of this cutting-edge medical sector. Cryoport's revenue growth is an indicator of the commercialization of new treatments, which are an important part of the future healthcare economy, as reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772561570658 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CYRX
Cryoport provides critical logistics solutions for the life sciences industry, transporting cell and gene therapies at ultra-low temperatures. This graph reflects the growing number of clinical trials and commercial drugs in this field, as each new client increases demand for its unique services.
Sales of companies in the market segment - Logist it
Cryoport, Inc. provides temperature-controlled logistics solutions for cell and gene therapy, where biomaterials require ultra-low temperatures during transportation. The company is a key partner for the biopharma industry. This chart shows the overall dynamics of the sector, reflecting the growth of the regenerative medicine industry, which cannot exist without Cryoport's specialized logistics.
Overall market sales
Cryoport provides critical logistics solutions for the biopharmaceutical industry, transporting cell and gene therapies at ultra-low temperatures. This growth, reflecting the life sciences sector's growth, is a direct driver for Cryoport. The development of cellular medicine is creating exponential demand for its unique services.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CYRX
Cryoport provides logistics solutions for cell and gene therapy requiring ultra-low temperatures. Future revenue growth is directly linked to the development of the entire biopharmaceutical industry. This graph essentially reflects analysts' predictions of an increase in the number of clinical trials and commercial launches of innovative cell and gene therapy products.
%20sales%20of%20the%20company%20CYRX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CYRX&v=1772561570881 "Schedule of future (projected) sales of the company CYRX")
Future (projected) sales of companies in the market segment - Logist it
Cryoport, Inc. provides temperature-controlled logistics solutions for cell and gene therapy. This chart shows projected revenues for the entire life sciences sector. It reflects expectations for increased clinical trials and commercial launches of biopharmaceuticals requiring Cryoport's unique services.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Logist%20it&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Logist-it&v=1772561570971 "Schedule of future (projected) sales of companies in the market segment - Logist it")
Future (projected) sales of the market as a whole
Cryoport provides logistics solutions for the biopharmaceutical industry, specializing in the transportation of cell and gene therapies at ultra-low temperatures. Its growth is directly linked to the development of this innovative medical sector. This graph, reflecting the investment climate, influences the financing of biotech companies—Cryoport's main clients.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772561570995 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CYRX
Cryoport provides logistics solutions for the biopharmaceutical industry, transporting cellular materials at ultra-low temperatures. This chart illustrates the profitability of this critically important niche service. The company's efficiency depends on pricing, managing complex logistics, and the ability to scale its unique solutions.
Market segment marginality - Logist it
Cryoport provides critical logistics solutions for cell and gene therapy, transporting biomaterials at ultra-low temperatures. This chart demonstrates the company's effectiveness in its unique and rapidly growing niche. These strong performance indicators demonstrate its leadership position and the value of its services to the biopharmaceutical industry.
Market marginality as a whole
Cryoport provides temperature-controlled logistics solutions for the life sciences industry, which is critical for cell and gene therapy. The company's profitability depends on the growth of this cutting-edge healthcare sector. This total market return chart highlights how Cryoport occupies an indispensable niche in the supply chain, ensuring sustainable growth regardless of general economic cycles.
Employees in the company, segment and market as a whole
Number of employees in the company CYRX
Cryoport provides critical logistics solutions for cell and gene therapies requiring ultra-low temperatures. This chart shows the growth of its specialized team. This expansion directly reflects the boom in biopharmaceuticals and the growing number of clinical trials and commercial drugs requiring a unique cold chain supply chain.
Share of the company's employees CYRX within the market segment - Logist it
This figure demonstrates Cryoport's critical role in modern medicine. The company's logistics team focuses on providing solutions for transporting biological materials at cryogenic temperatures. These specialists ensure a reliable cold chain for cell and gene therapy, vaccines, and reproductive materials.
Number of employees in the market segment - Logist it
Cryoport provides logistics solutions for the biopharmaceutical industry that require ultra-low temperatures, such as transporting gene therapy cells. This is a critical niche. This graph illustrates how advances in biotechnology are creating demand for new services and specialists in complex cold chain management, where Cryoport is a leader.
Number of employees in the market as a whole
Cryoport, Inc. provides logistics solutions for cell and gene therapy. Its business is growing alongside the regenerative medicine industry and is independent of the overall employment shown in this graph. The company is critical infrastructure for the medicine of the future, where "drugs" are living cells.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CYRX (CYRX)
Cryoport provides logistics solutions for cell and gene therapy requiring ultra-low temperatures. This chart shows how the market values its unique infrastructure. Its high market capitalization per employee indicates that the company has created an indispensable and technologically sophisticated service whose value far exceeds the value of its physical assets.
%20of%20the%20company%20CYRX%20(CYRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CYRX-CYRX&v=1772561571487 "Chart of market capitalization per employee (in thousands of dollars) of the company CYRX (CYRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Logist it
Cryoport provides logistics solutions for cell and gene therapy, where every detail matters. The high cost per employee in this niche reflects the critical importance and technological complexity of its services. The chart shows how the market values the company's unique expertise and infrastructure for ensuring the safety of biomaterials.
%20by%20market%20segment%20-%20Logist%20it&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Logist-it&v=1772561571544 "Market capitalization per employee (in thousands of dollars) by market segment - Logist it")
Market capitalization per employee (in thousands of dollars) for the overall market
Cryoport, Inc. provides logistics solutions for the biopharmaceutical industry requiring ultra-low temperatures. This chart shows how the market values its unique and critical niche. The company's per-employee value is high because it provides more than just transportation, but a high-tech service for cell and gene therapy.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772561571653 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CYRX (CYRX)
Cryoport provides logistics solutions for cell and gene therapy. They transport biomaterials at ultra-low "cryo" temperatures. This is a critical B2B service. This chart shows the profitability of this niche. Every Cryoport employee ensures the safety of this precious cargo, which allows the company to charge a premium price.
%20Chart%20CYRX%20(CYRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CYRX-CYRX&v=1772561571709 "Company Profit Per Employee (in thousands of dollars) Chart CYRX (CYRX)")
Profit per employee (in thousands of dollars) in the market segment - Logist it
Cryoport provides logistics solutions for cell and gene therapies requiring ultra-low temperatures (cryogenics). This is a critical niche in modern medicine. This chart demonstrates how effectively the company monetizes its unique logistics services. It serves as a benchmark for assessing how far Cryoport is ahead of its competitors in managing the complex and expensive cold chain for biopharma.
%20in%20the%20market%20segment%20-%20Logist%20it&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Logist-it&v=1772561571827 "Chart of profit per employee (in thousands of dollars) in the market segment - Logist it")
Profit per employee (in thousands of dollars) for the market as a whole
Cryoport (CYRX) provides logistics solutions for cell and gene therapy, transporting biomaterials at ultra-low temperatures (cryogenics). This is a critical niche service. This chart demonstrates the demand for their unique containers and services. Increasing revenue per employee means that more and more biotech companies trust them to transport their valuable samples, and Cryoport effectively manages its fleet and staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772561571903 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CYRX (CYRX)
Cryoport provides logistics solutions for cell and gene therapy requiring ultra-low temperatures. This chart illustrates how the company has become a critical link in modern medicine. Its high revenue per employee is a result of providing unique and indispensable services to the biopharmaceutical industry.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CYRX-CYRX&v=1772561571914 "Sales chart per company employee CYRX (CYRX)")
Sales per employee in the market segment - Logist it
Cryoport provides temperature-controlled logistics solutions (cryogenic logistics) for cell and gene therapy. This chart shows the average revenue per employee in this segment. This is a critical niche in biotech. This metric demonstrates how productive their service model is compared to other specialized logistics operators.
Sales per employee for the market as a whole
Cryoport provides critical logistics services for the biopharmaceutical industry. They facilitate the transportation of cell and gene therapies at ultra-low temperatures (cold chain). This is a niche B2B service. This graph shows the significant revenue their team generates by managing the complex and indispensable logistics of life-saving drugs.
Short shares by company, segment and market as a whole
Shares shorted by company CYRX (CYRX)
Cryoport provides logistics solutions (containers, tracking) for biopharma at ultra-low temperatures, which is critical for cell and gene therapy. The bearish sentiment seen in this chart may be related to the slowdown in the biotech sector. Reduced R&D budgets and the number of clinical trials are directly impacting demand for Cryoport's services.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CYRX-CYRX&v=1772561572062 "Short Shares Chart for the Company CYRX (CYRX)")
Shares shorted by market segment - Logist it
Cryoport provides critical logistics solutions (liquid nitrogen containers, monitoring) for the transportation of cell and gene therapy materials. This chart reflects the overall sentiment in the sector. It reflects investor concerns that the pace of gene therapy development will slow, reducing demand for complex cold chain logistics across the industry.
Shares shorted by the overall market
Cryoport provides ultra-cold logistics for cell therapy—a bonanza for biotech. However, its clients are often unprofitable R&D companies. When this market fear indicator rises, it signals a "venture winter." Investors expect Cryoport's clients to freeze clinical trials, which directly impacts demand for its services.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CYRX (CYRX)
Cryoport (CYRX) is a leader in cold chain logistics for the life sciences. They provide specialized containers and services for transporting critical biomaterials (such as cell therapy) at ultra-low temperatures. This chart measures the hype. It shows "overheating" (above 70) amid a boom in cell therapy, or "overselling" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CYRX-CYRX&v=1772561572199 "RSI 14 indicator chart for the company's stock CYRX (CYRX)")
RSI 14 Market Segment - Logist it
Cryoport (CYRX) is a leader in medical cold chain solutions. They provide logistics solutions (containers, monitoring) for transporting critical cell and gene therapies at ultra-low temperatures. This chart measures the pulse of the Logistics/IT sector. It helps us understand whether CYRX is riding the biotech boom or a general trend.
RSI 14 for the overall market
Cryoport (CYRX) provides cold chain logistics for biotech companies. This chart is an indicator of R&D health. In the euphoria of pharma, biotech companies (CYRX clients) are generously funded and launch hundreds of clinical trials. In the panic, R&D funding freezes, the number of trials drops, and demand for CYRX's niche services declines.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CYRX (CYRX)
Cryoport (CYRX) is a leader in temperature-controlled logistics (cold chain) for the life sciences sector. The company transports critical biomaterials (cell and gene therapies) in specialized containers. This chart shows the average analyst forecast, reflecting their expectations for the growth of clinical trials and commercialization of cell therapies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CYRX-CYRX&v=1772561572354 "A chart showing analyst consensus forecasts for the expected stock price. CYRX (CYRX)")
The difference between the consensus estimate and the actual stock price CYRX (CYRX)
Cryoport (CYRX) is a leader in cold chain logistics for cell and gene therapy. Their smart containers (shippers) provide ultra-low temperatures for transporting live cells. This chart shows their R&D infrastructure assessment. It measures the gap between their price and the consensus target, reflecting their perceived growth potential in the regenerative medicine market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CYRX-CYRX&v=1772561572385 "A chart showing the difference between the consensus forecast and the actual stock price. CYRX (CYRX)")
Analyst consensus forecast for stock prices by market segment - Logist it
Cryoport is the cold chain logistics provider for the future of medicine. The company provides critical transportation of cell and gene therapies at ultra-low temperatures. This chart shows analysts' overall expectations across the IT logistics (and biotech) sector. It reflects whether experts believe the cell therapy market, on which Cryoport is directly dependent, will experience explosive growth.
Analysts' consensus forecast for the overall market share price
Cryoport provides critical logistics solutions (containers, monitoring) for the transportation of sensitive biological materials (cell therapy, vaccines) at ultra-low temperatures. This chart shows the overall market sentiment. For Cryoport, whose business is the "logistics of life," the overall optimism is important because it reflects growth in the biotech sector, their key client.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CYRX
Cryoport (CYRX) is the FedEx of cell therapy. They provide critical, ultra-cold (cryogenic) logistics solutions for transporting live drugs (gene therapy, CAR-T). This graph is a biotech pick and shovel. Its dynamics are a barometer of the R&D and commercialization of cell therapies, which cannot exist without their cold chain.
AKIMA Market Segment Index - Logist it
Cryoport (CYRX) is the FedEx of cell therapy; the company is the undisputed leader in cryogenic logistics—providing specialized containers and services for transporting frozen live cells (for R&D and therapeutics). This aggregate metric evaluates companies. The chart shows the sector average. This benchmark: how does this critical (and niche) model (CYRX) differentiate it from the average competitor?
The AKIM Index for the overall market
Cryoport is a leader in temperature-controlled logistics for the life sciences industry (cell therapy, IVF). This chart, reflecting the market average, is a backdrop. It helps assess how CYRX, a critical partner for biopharma, compares to overall macroeconomic trends and clinical trial activity.
